Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Clinical stage biopharmaceutical company Faron Pharmaceuticals said it had signed a sub-license agreement for the rights to U.S. patent related to patent related to Traumakine.
Traumakine is intended for to treat capillary leak and systemic inflammatory response syndromes including acute respiratory distress syndrome (ARDS) in the U.S.
Patent US9,376,478 currently extends to 2033.
At 8:47am: (LON:FARN) Faron Pharmaceuticals share price was 0p at 275p